Table 3.
All Adverse Event | AGS-16M8F(Hyb) N=26 | AGS-16C3F(CHO) N=34 |
---|---|---|
Subjects with at least 1 event | 26 (100%) | 34 (100%) |
Fatigue | 12 (46.2%) | 24 (70.6%) |
Nausea | 7 (26.9%) | 19 (55.9%) |
Dry eye | 17 (50.0%) | |
Decreased appetite | 15 (44.1%) | |
Vision blurred | 15 (44.1%) | |
Vomiting | 13 (38.2%) | |
Thrombocytopenia | 8 (30.8%) | 12 (35.3%) |
Headache | 11 (32.4%) | |
Keratitis | 11 (32.4%) | |
Anaemia | 10 (29.4%) | |
Constipation | 8 (30.8%) | 10 (29.4%) |
Dyspnoea | 7 (26.9%) | 10 (29.4%) |
Pyrexia | 8 (23.5%) | |
Epistaxis | 7 (20.6%) | |
Infusion related reaction | 7 (20.6%) | |
Oedema peripheral | 7 (20.6%) |